Diabetic Cardiomyopathies
"Diabetic Cardiomyopathies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Descriptor ID |
D058065
|
| MeSH Number(s) |
C14.280.238.235 C19.246.099.625
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Diabetic Cardiomyopathies".
Below are MeSH descriptors whose meaning is more specific than "Diabetic Cardiomyopathies".
This graph shows the total number of publications written about "Diabetic Cardiomyopathies" by people in this website by year, and whether "Diabetic Cardiomyopathies" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 2 | 4 |
| 2013 | 2 | 0 | 2 |
| 2015 | 0 | 1 | 1 |
| 2017 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diabetic Cardiomyopathies" by people in Profiles.
-
Autophagy Inhibition Enables Nrf2 to Exaggerate the Progression of Diabetic Cardiomyopathy in Mice. Diabetes. 2020 12; 69(12):2720-2734.
-
Maintaining Myocardial Glucose Utilization in Diabetic Cardiomyopathy Accelerates Mitochondrial Dysfunction. Diabetes. 2020 10; 69(10):2094-2111.
-
Association of Diabetes Mellitus on Cardiac Remodeling, Quality of Life, and Clinical Outcomes in Heart Failure With Reduced and Preserved Ejection Fraction. J Am Heart Assoc. 2019 09 03; 8(17):e013114.
-
Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF. JACC Heart Fail. 2019 06; 7(6):457-465.
-
Sulforaphane prevents angiotensin II-induced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK-3?/Fyn pathway. Redox Biol. 2018 05; 15:405-417.
-
Incidence and Mortality Rates and Clinical Characteristics of Type 1 Diabetes among Children and Young Adults in Cochabamba, Bolivia. J Diabetes Res. 2017; 2017:8454757.
-
Opposite associations between alanine aminotransferase and ?-glutamyl transferase levels and all-cause mortality in type 2 diabetes: Analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Metabolism. 2016 May; 65(5):783-793.
-
The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications. 2013 May-Jun; 27(3):280-6.
-
Prevention by sulforaphane of diabetic cardiomyopathy is associated with up-regulation of Nrf2 expression and transcription activation. J Mol Cell Cardiol. 2013 Apr; 57:82-95.
-
Therapeutic effect of MG-132 on diabetic cardiomyopathy is associated with its suppression of proteasomal activities: roles of Nrf2 and NF-?B. Am J Physiol Heart Circ Physiol. 2013 Feb 15; 304(4):H567-78.